New drug combo aims to boost platelets in severe ITP patients
NCT ID NCT07189910
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a treatment plan for adults with severe immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants will receive steroids and a platelet-boosting drug in the hospital for 14 days, followed by a 10-week course of an oral medication at home. The goal is to see if this sequence improves platelet counts and reduces relapses compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital
Wuhan, Hubei, 430022,, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.